Precision Strategies in Cutaneous Malignancies: From Molecular Drivers to Durable Immunologic Control
DOI:
https://doi.org/10.64784/147Keywords:
cutaneous oncology, melanoma, precision medicine, BRAF mutation, immune checkpoint inhibitors, PD-1 blockade, targeted therapy, molecular risk stratification, genomic testing, Merkel-cell carcinoma, early detection, AJCC staging, immunotherapy durability, combination therapy, global oncologyAbstract
Cutaneous oncology has entered a new phase defined by the integration of early detection strategies, molecular risk stratification, and biologically guided systemic therapies. Melanoma, although less frequent than keratinocyte cancers, remains the most lethal form of skin cancer, while basal cell carcinoma and Merkel-cell carcinoma contribute significantly to global oncologic burden. This review analyzes the contemporary transformation of cutaneous oncology within the precision medicine framework, focusing on three core domains: stage-based prognosis, genomic characterization, and targeted and immune-based therapeutic interventions. Evidence from landmark clinical trials demonstrates that BRAF-mutated melanoma benefits from combined BRAF/MEK inhibition, while immune checkpoint blockade—particularly PD-1–based regimens—achieves durable survival in advanced disease. Long-term survival data confirm sustained benefit in a subset of patients, redefining expectations for metastatic melanoma outcomes. In addition, immunotherapy has shown meaningful activity in other aggressive cutaneous malignancies such as Merkel-cell carcinoma. The integration of staging systems, molecular diagnostics, and systemic therapies illustrates a dual therapeutic paradigm in which tumor genotype and immune context guide treatment selection. From an international perspective, including healthcare systems in Mexico, Colombia, and Ecuador, the implementation of precision oncology requires structured integration of early detection, standardized pathology, essential genomic testing, and multidisciplinary therapeutic access. Cutaneous oncology in the precision era is therefore characterized by coordinated biological insight and clinical application, forming the basis for advanced academic instruction and evidence-based oncologic practice.
References
[1] D. Schadendorf et al., “Melanoma,” Lancet, vol. 392, no. 10151, pp. 971–984, 2018, doi: 10.1016/S0140-6736(18)31559-9.
[2] A. Ribas and J. D. Wolchok, “Cancer immunotherapy using checkpoint blockade,” Science, vol. 359, no. 6382, pp. 1350–1355, 2018, doi: 10.1126/science.aar4060.
[3] J. Larkin et al., “Combined nivolumab and ipilimumab in advanced melanoma,” N. Engl. J. Med., vol. 373, no. 1, pp. 23–34, 2015, doi: 10.1056/NEJMoa1504030.
[4] G. V. Long et al., “Dabrafenib and trametinib in BRAF-mutated melanoma,” N. Engl. J. Med., vol. 371, no. 20, pp. 1877–1888, 2014, doi: 10.1056/NEJMoa1406037.
[5] P. A. Ascierto et al., “The role of BRAF V600 mutation in melanoma,” Lancet Oncol., vol. 13, no. 10, pp. e501–e512, 2012, doi: 10.1016/S1470-2045(12)70219-7.
[6] H. Davies et al., “Mutations of the BRAF gene in human cancer,” Nature, vol. 417, no. 6892, pp. 949–954, 2002, doi: 10.1038/nature00766.
[7] C. Robert et al., “Pembrolizumab versus ipilimumab in advanced melanoma,” N. Engl. J. Med., vol. 372, no. 26, pp. 2521–2532, 2015, doi: 10.1056/NEJMoa1503093.
[8] A. J. Lazar et al., “Targeted therapy in melanoma,” Nat. Rev. Cancer, vol. 14, no. 3, pp. 205–218, 2014, doi: 10.1038/nrc3678.
[9] J. E. Gershenwald et al., “Melanoma staging: AJCC 8th edition,” CA Cancer J. Clin., vol. 67, no. 6, pp. 472–492, 2017, doi: 10.3322/caac.21409.
[10] E. B. Hawryluk and M. L. Tsao, “Advances in early melanoma detection,” JAMA Dermatol., vol. 155, no. 8, pp. 889–896, 2019, doi: 10.1001/jamadermatol.2019.0900.
[11] A. Ribas et al., “Oncolytic virotherapy in melanoma,” Nat. Med., vol. 23, no. 3, pp. 287–289, 2017, doi: 10.1038/nm.4296.
[12] S. Queirolo and P. A. Ascierto, “Combination therapy in melanoma,” Lancet Oncol., vol. 20, no. 7, pp. e341–e352, 2019, doi: 10.1016/S1470-2045(19)30259-5.
[13] H. K. Lee et al., “PD-L1 expression as predictive biomarker,” Clin. Cancer Res., vol. 22, no. 23, pp. 5454–5463, 2016, doi: 10.1158/1078-0432.CCR-16-1329.
[14] C. M. Olsen et al., “Global incidence of keratinocyte cancers,” J. Invest. Dermatol., vol. 139, no. 3, pp. 533–542, 2019, doi: 10.1016/j.jid.2018.08.025.
[15] M. C. Mihm and J. R. Scolyer, “Pathology of melanoma,” Lancet, vol. 379, no. 9816, pp. 549–559, 2012, doi: 10.1016/S0140-6736(11)61349-5.
[16] A. A. Sekulic et al., “Vismodegib in advanced basal-cell carcinoma,” N. Engl. J. Med., vol. 366, no. 23, pp. 2171–2179, 2012, doi: 10.1056/NEJMoa1113713.
[17] R. J. Motzer et al., “Targeted therapies in solid tumors,” N. Engl. J. Med., vol. 378, no. 18, pp. 1685–1686, 2018, doi: 10.1056/NEJMc1801477.
[18] S. Y. Wong et al., “Genomic testing and precision oncology in melanoma,” Nat. Rev. Clin. Oncol., vol. 18, no. 9, pp. 567–584, 2021, doi: 10.1038/s41571-021-00498-5.
[19] P. Nghiem et al., “Pembrolizumab in advanced Merkel-cell carcinoma,” N. Engl. J. Med., vol. 374, no. 26, pp. 2542–2552, 2016, doi: 10.1056/NEJMoa1603702.
[20] C. Robert et al., “Five-year outcomes with nivolumab in advanced melanoma,” N. Engl. J. Med., vol. 381, no. 16, pp. 1535–1546, 2019, doi: 10.1056/NEJMoa1906669.
